Emakakaela patoloogia 1.
|
|
|
- Lambert Potter
- 5 years ago
- Views:
Transcription
1 Günekoloogiline patoloogia Emakakaela patoloogia 1. Ave Minajeva
2 Kirjandus Diane Solomon (Ed), Ritu Nayar. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes. Secon edition. Bethesda system web atlas
3 Kirjandust eesti keeles: Minajeva, A. (2007). Inimese papilloomiviirusest tingitud p16 (üle)ekspressiooni immunohistokeemiline hindamine emakakaelavähi ja düsplaasiate diferentsiaaldiagnostikas. Eesti Arst, 86,
4 Cervical cancer incidence and mortality are related to cytological screening
5 Güneko-tsütoloogilise uuringu tehnika kanal portio üleminekutsoon Ayre spaatel endotserviksi hari
6 Hari (endotserviks) Ayre spaatel (cul- de- sac) Ayre spaatel (täiustatud)
7 Cul de sac (kotipõhi) günekoloogilises anatoomias
8 kahemomentne materjali klaasile kandmine emakakaela portio kanalist, emakaõõnest
9 Täiustatud Ayre spaatel võimaldab ka ühemomentset materjali pealekandmist
10 Papanicolaou värving (Pap värving) Multikromaatiline värvimismeetod histoloogilisele ja tsütoloogilisele materjalile. George Papanicolaou: Kaasaegse kliinilise tsütoloogia rajaja. Georgios Nicholas Papanikolaou (George Papanicolaou)
11 Rakuliigid PAP testis vastavalt anatoomilisele paiknemisele TRANSFORMATSIONI- TSOONIST: METAPLASTILINE LAMEEPITEEL KAELA- KANALIST: SILINDER (NÄÄRME-) EPITEEL PORTIO: LAMEEPITEEL
12 Endotservikaalne silinderepiteel (cervical columnar epithelium) histoloogiliselt
13 Histoloogiliselt esineb tupes ja emakakaela tuppe ulatuval osal (nn. portiol) mitmekihiline lameepiteel, millele tsütoloogiliselt vastab 3 liiki rakke: pinnakiht pindmise vahekihi vahekiht sügava kihi rakud. parabasaalkihid basaalkiht süvakiht basaalkiht
14 Milliseid prekantseroosseid muutusi uuritakse ja kuidas neid klassifitseeritakse?
15 Emakakaela vähieelsed seisundid Histoloogilised terminid CIN Cervical Intraepithelial Neoplasia CIN 1 = nõrk düsplaasia CIN 2 = mõõdukas düsplaasia CIN 3 = raske düsplaasia ja Carcinoma in situ Tsütoloogilised terminid SIL Squamous Intraepithelial Lesion LSIL - low-grade SIL (vastab CIN1) HSIL (high-grade SIL) = (vastab CIN2 ja CIN3)
16 Cervical Precancerous States Histology CIN Cervical Intraepithelial Neoplasia CIN 1 = mild dysplasia CIN 2 = modarate dysplasia CIN 3 = severe dysplasia and Carcinoma in situ Cytology SIL Squamous Intraepithelial Lesion LSIL - low-grade SIL (correlated to CIN1) HSIL (high-grade SIL) = (correlated to CIN2 and CIN3)
17 Kaks süsteemi PAP süsteem Bethesda süsteem loodud a. Dr. George Papanicolau poolt.koostatud erialaspetsialistide poolt
18 The Bethesda System for Cytological Diagnosis Papanicolau stain of cervical smear Specimen adequacy * Description NILM - Negative for Intraepithelial Lesion and Malignancy (PAP I-II) Normal Infections Reactive and reparative cell changes Pathological changes (squamous and columnar epithelium)
19 Pathological Changes of squamous epithelium in Cytology Changes suggestive of SIL ASC-US - Atypical Squamous Cells of Undetermined Significance ASC-H Atypical Squamous Cells, cannot exclude HSIL SIL Squamous Intraepithelial Lesion LSIL - low-grade SIL HPV related cell changes, mild dysplasia (histologically CIN1) HSIL - high-grade SIL (histologically CIN2 and CIN3) Moderate dysplasia (histologically CIN2) Severe dysplasia (histologically CIN3) Carcinoma in situ Squamous cell carcinoma
20 PAP klassifikatsioon Bethesda süsteem PAP I PAP II Norm normipärased rakud. reaktiivsete muutustega rakud ASC-US ASC-H üksikud atüüpilised rakud PAP IIIa LGSIL nõrk düsplaasia PAP III PAP IIIb HGSIL mõõdukas düsplaasia tugev düsplaasia PAP IV üksikud vähirakud PAP V emakakaela vähk emakakaela vähk
21 Emakakaela düspaasia etiopatogenees selle seos erinevate düsplaasia astmetega.
22 Inimese papilloomiviirus, HPV Emakakaelavähi ja vähieelsete seisundite etioloogiliseks teguriks on HPV viirus (papovaviridae). 1 kaheahelaline DNA molekul (kõik geenid kodeeritakse ühel DNA ahelal)
23 H P V t ü ü b i d t o i m e HPV madal risk 6, 11, 42 HPV kõrge risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 naha ja limaskesta näsalised vohandid kondüloomid (papilloomid), kerge atüpism limaskestade vähieelsed seisundid vähk Erinevad tüved, mis infitseerivad alumist genitaaltrakti, jagunevad: Madala riskiga HPV tüved - on seotud kondüloomidega ja nõrga düsplaasiaga. Kõrge riskiga HPV tüved - põhjustavad emakakaela rasket düsplaasiat ja invasiivset vähki;
24
25
26
27 Patogenees
28 Viirused nakatavad lameepiteeli basaalseid rakke (jagunemisvõimelised rakud). Viirus tungib basaalrakkudeni läbi epiteeli mikroabrasioonide.
29 LATENTNE FAAS: Viiruskoopiate arv püsib konstantne mitme rakupõlvkonna vältel. Latentses faasis infektsioon võib kliinilselt mitte avalduda.
30 HPV võib säilitada oma genoomi püsiva ekstrakromosomaalse elemendina rakutuumas episomaalses vormis (madala riskiga HPV tüved):
31 PRODUKTIIVNE FAAS: Nakatunud rakud liiguvad epiteeli küpsemise käigus pindmistesse kihtidesse. Küpsetes rakkudes algab viiruse vegetatiivne replikatsioon pakitud viiruspartiklid jõuavad koos surnud rakkudega limaskesta pinnale.
32 Viiruspartiklid elektronmikroskoopiliselt Rakutuumast vabanevad viiruspartiklid lõhustavad tsütoskeletti halo tuuma ümber: koilotsüüt (Kr. tühi).
33 Kliiniliselt kondüloomid kolposkoopia
34 Progresseerumine raskeks düsplaasiaks ja vähiks: persisteeruv suure riskiga HPV infektsioon. Viiruse DNA integreerub peremeesraku genoomi.
35 Viiruse onkoproteiinide ekspressioon E6 E7 p53 inhibeerib prb Tuumorsupressorgeenid
36 Viiruse onkoproteiinide toime E6 E7 inhibeerib prb Tuumorsupressorgeen inhibeerib P16(INK4a) üleekspressioon Tsükliinsõltuva kinaasi inhibiitor
37 P16 üleekpressiooni saab raskes düsplaasias ja vähis immunohistokeemiliselt hinnata P16 positiivne värving kattub düsplaasia ulatusega. Mõõdukas düsplaasia (CIN II)
38 H&E p16 Raske düsplaasia (CINIII): düsplastilised rakud kogu epiteeli paksuses.
39 H&E p16 Invasiivne vähk
40 CIN- cervical intraepithelial neoplasia = histoloogiline termin! CIN diagnoos põhineb tuumade atüpismi astmel ja lameepiteeli küpsemise häirumisel ( kaob epiteeli polaarsus) Low-grade madala astme kahjustus: CIN1: sage iseeneslik regressioon, vajalik jälgimine progressiooni suhtes High grade kõrge astme kahjustus (CIN2 ja CIN3): konisatsioon. SIL ja CIN vastavus:
41
42 CIN related to SIL
43 Lameepiteeli düsplaasia astmed: intraepiteliaalne neoplaasia (CIN) histoloogiliselt
44 CIN 1 puhul sageli epiteeli pindmises kihis HPV infekts tunnused, koilotsütoos, düskeratoos, tuumade hüperkromaasia, hulgituumsed rakud, ebaühtlane tuuma kontuur. Erinevalt HSIL-st säilub epiteeli kihinine küpsemine ning mitoose näeb ainult basaalses/parabasaalses kihis. Düsplastilisi ebaküpseid rakke ainult epiteeli basaalses 1/3. NORM CIN 1
45 CIN 2 korral võib pinnakihis olla HPV kahjustust ja epiteeli pindmises osas säilub küpsemine. CIN 3 korral mitte. CIN 2-CIN 3. Tuumade tugev atüpism epiteeli süvakihtides. Tuuma/tsütoplasma suhe, hüperkromaasia, tuumade kontuur ebaühtlane. Mitoosid, neid võib leida epiteeli pindmises ½. Võib esineda atüüpilisi mitoose. Rakulise polaarsuse kadumine. CIN 2 Ki 67: mitooside arvu CIN 3
46 Progression of HPV-induced lesion
47 HSIL puhul (CIN II-CIN III) emakakaela konisatsioon.
48 Konisatsioonimaterjal reeglina uuritakse patoloogiliselt täies ulatuses. Võimalusel märgitakse, kas konisaadi lõikepiir düsplaasiavaba
49 Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Emakakaelakanal, mida kattev metaplastiline lameepiteel on raske düsplaasia tunnustega. Endostervikaalsed näärmed
50 Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Emakakaelakanal, mida kattev metaplastiline lameepiteel on raske düsplaasia tunnustega. Endostervikaalsed näärmed
51 Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Endostervikaalsed näärmed Raske düsplaasia: kogu lameepiteeli paksuses atüüpilised rakud, mitoosid
52 Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Düsplastilised rakud tungimas metaplastilistesse endotservikaalsetesse näärmetesse
53 Mikropreparaat Gy44. Dysplasia epithelii gravis (CIN III) Emakakaela konisaadis. Raske düsplaasia: kogu lameepiteeli paksuses atüüpilised rakud, mitoosid
54 CIN 3 hõlmab rasket düsplaasiat ja carcinoma in situ, mõlemad mitteinvasiivset vähieelsed seisundid. Kui olla täpne, siis carcinoma in situ puhul: 1. Puudub rakkude küpsemine kogu epiteeli paksuses. 2. Pindmise kihi rakud võivad olla lamenenud.
55 Invasiivne kartsinoom
56 Sarvestuv lamerakk-kartsinoom Mittesarvestuv lamerakk-kartsinoom
57 Mikropreparaat Gy 43. Emakakaela sarvestuv lamerakuline kartsinoom Normaalne mitmekihiline lameepiteel Sarvestuv lamerakuline kartsinoom: Invasiivne kasv emakakaela stroomasse
58 Mikropreparaat Gy 43. Emakakaela sarvestuv lamerakuline kartsinoom (G2) Kartsinoomikolded invasiivne kasv: Kollete servas strooma desmoplastiline reaktsioon Atüüpiliste lameepiteelirakkude kollete keskosas sarvestunud rakke
59 Edaspidi tutvume lähemalt PAP testiga ja näärmeepiteeli muutustega.
Understanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
Colposcopy. Attila L Major, MD, PhD
Colposcopy Attila L Major, MD, PhD Histology Colposcopy Cytology It has been estimated that annual Pap smear testing reduces a woman s chance of dying of cervical cancer from 4 in 1000 to about 5 in 10,000
Should Anal Pap Smears Be a Standard of Care in HIV Management?
Should Anal Pap Smears Be a Standard of Care in HIV Management? Gordon Dickinson, M.D., FACP Professor of Medicine and Chief Infectious Diseases, Miller School of Medicine Short Answer: NO But 15-20 HPV
Cervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
Histopathology: Cervical HPV and neoplasia
Histopathology: Cervical HPV and neoplasia These presentations are to help you identify basic histopathological features. They do not contain the additional factual information that you need to learn about
Cervical Cancer : Pap smear
Taking a PAP SMEAR Cervical Cancer : Pap smear George N Papanicolaou introduced cervical cytology in clinical practice in 1940 In 1945, PAP smear was endorsed by American cancer society as an effective
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way
ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING Central Valley Public Health: Women's Way ICD-9-CM (Top 35) ICD-10-CM ICD-10-CM Description COMMENTS V10.3: Personal history of malignant neoplasm of Z85.3
Clinical Practice Guidelines June 2013
Clinical Practice Guidelines June 2013 General Principles: The Papanicolaou (Pap) smear is widely credited with reducing mortality from cervical cancer, and remains the single best method for the early
chapter 4. The effect of oncogenic HPV on transformation zone epithelium
chapter 4. The effect of oncogenic HPV on transformation zone epithelium CHAPTER 1 All squamous cervical cancer (and probably all cervical adenocarcinoma) is associated with oncogenic HPV, and the absence
SQUAMOUS CELLS: Atypical squamous cells (ASC) - of undetermined significance (ASC-US) - cannot exclude HSIL (ASC-H)
SQUAMOUS CELLS: Atypical squamous cells (ASC) - of undetermined significance (ASC-US) - cannot exclude HSIL (ASC-H) ASC refers to cytologic changes suggestive of SIL, which are qualitativley or quantitatively
Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.
CLINICAL PRACTICE GUIDELINE Guideline Number: DHMP_DHMC_PG1015 Guideline Subject: Routine Cervical Cancer Screening Effective Date: 9/2018 Revision Date: 9/2019 Pages: 2 of 2 Quality Management Committee
The Korean Journal of Cytopathology 13(1): 14-20, 2002
13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
BC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals
PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals Historical Named after George Papanicolaou, a Greek American Studied cervical epithelium in menstrual cycle of guinea
Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH
Cervical Testing and Results Management An Evidenced-Based Approach April 22nd, 2010 Debora Bear, MSN, MPH Assistant Medical Director for Planned Parenthood of New Mexico, Inc. Burden of cervical cancer
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series
HPV and Cervical Cancer, Screening and Prevention John Ragsdale, MD July 12, 2018 CME Lecture Series We have come a long Way Prevalence HPV in Young Adults in U.S HPV genotypes 55-60% of All cancers 20%
1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal
Diseases of cervix I. Inflammations 1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal squamous mucosa
Int. J. Life. Sci. Scienti. Res., 2(3): (ISSN: ) Impact Factor 2.4 MAY Research Article (Open access)
Int. J. Life. Sci. Scienti. Res., 2(3): -279-284 (ISSN: 2455-1716) Impact Factor 2.4 MAY-2016 Research Article (Open access) Detection of Abnormal Cervical Cytology by Papanicolaou Stained (PAP) Smears
Tsütoloogia patoloogia osana tänapäeva meditsiinis
Tsütoloogia patoloogia osana tänapäeva meditsiinis Eesti Arst 2002; 81 (12): 789 794 Natalia Lapidus Põhja-Eesti Regionaalhaigla Hiiu patoloogiaosakond tsütoloogia, ajalugu, materjali võtmine ja töötlemine,
Cytology Report Format
Squamous Precursor Lesions and Malignancies In Pap Test Dina R. Mody, MD, FCAP Director of Cytology The Methodist Hospital, Houston, TX Professor of Pathology and Laboratory Medicine Weill Medical College
Making Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation
Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation May Yu Director of Cytology Laboratory Service Department of Anatomical & Cellular Pathology Prince of Wales Hospital Cervical
PAP smear. (Papanicolaou Test)
PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European
Eradicating Mortality from Cervical Cancer
Eradicating Mortality from Cervical Cancer Michelle Berlin, MD, MPH Vice Chair, Obstetrics & Gynecology Associate Director, Center for Women s Health June 2, 2009 Overview Prevention Human Papilloma Virus
New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology
New Diagnoses Need New Approaches: A Glimpse into the Near Future of Gynecologic Pathology United States and Canadian Academy of Pathology 102 nd Annual Meeting Baltimore, Maryland Christina S. Kong, M.D.
International Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Cytodiagnostic Study of Cervical Lesions Using the Bethesda System with Histopathological Tahera
WELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1
WELL WOMAN CLINIC-SCREENING PROGRAM FOR CERVICAL CARCINOMAS G. J. Vani Padmaja 1 HOW TO CITE THIS ARTICLE: G. J. Vani Padmaja. Well Woman Clinic-Screening Program for Cervical Carcinomas. Journal of Evolution
BCCCP Approved ICD-9 Code List Fiscal Year 2010
BCCCP Approved ICD-9 List Fiscal Year 2010 Diagnosis Description 174.0 Malignant neoplasm of female breast; Nipple and areola 174.1 Malignant neoplasm of female breast; Central portion 174.2 Malignant
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests
ASCCP 2013 Guidelines for Managing Abnormal Cervical Cancer Screening Tests www.treatmentok.com Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Ann Arbor, Michigan Disclosures
Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear
The Korean Journal of Pathology 2010; 44: 528-35 DOI: 10.4132/KoreanJPathol.2010.44.5.528 Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions
The Bethesda System: Updates for th Cytopathology Congress Bursa, Turkey October 14, 2015
HARVARD MEDICAL SCHOOL The Bethesda System: Updates for 2015 6th Cytopathology Congress Bursa, Turkey October 14, 2015 David C. Wilbur, M.D. Dept. of Pathology Massachusetts General Hospital DISCLOSURES
GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital
GYN (Glandulars) Still Difficult After All These Years! Dina R Mody, MD Director of Cytology Laboratories and fellowship Program Methodist Hospital and Bioreference Labs (Houston) Department of Pathology
Table of Contents. 1. Overview. 2. Interpretation Guide. 3. Staining Gallery Cases Negative for CINtec PLUS
Staining Atlas Table of Contents 1. Overview 1.1 Introduction 1.2 Role of p16 INK4a 1.3 Role of Ki-67 1.4 Molecular Pathogenesis 1.5 p16 INK4a Expression in Cervical Dysplasia 1.6 The Concept of CINtec
Chapter 10: Pap Test Results
Chapter 10: Pap Test Results On completion of this section, the learner will be able to: 1. Identify how Pap test results are interpreted and the reasons for normal and abnormal results. 2. Describe the
What is a Pap smear?
Pap smear What is a Pap smear? A Pap smear is a test that checks for changes in the cells of your cervix. The cervix is the lower part of the uterus that opens into the vagina. Developed over forty years
Detecting High-Grade Cervical Disease on ASC-H Cytology. Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing
Anatomic Pathology / BD ProEx C Use in ASC-H Cy t o l o g y Detecting High-Grade Cervical Disease on ASC-H Cytology Role of BD ProEx C and Digene Hybrid Capture II HPV DNA Testing Momin T. Siddiqui, MD,
The ABCs of TBS. A Novice's Guide to the Bethesda System
CE U P D A T E W O M E N ' S HEALTH III Julia Woodruff Wildes, MD The ABCs of TBS A Novice's Guide to the Bethesda System This is the third and final article in a three-part series on women's health. The
EU guidelines for reporting gynaecological cytology
EU guidelines for reporting gynaecological cytology Amanda Herbert Guy s & St Thomas Foundation NHS Trust 5th EFCS Annual Tutorial, Trondheim, Norway 28 th May 1 st June 2012 EU guidelines aim to harmonize
Management Algorithms for Abnormal Cervical Cytology and Colposcopy
Management Algorithms for Abnormal Cervical Cytology and Colposcopy Table of Contents Standard Colposcopic Definitions... 1 Guidelines for the Assessment of Abnormal Cervical Cytology... 2 Ia: Persistent
CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN)
CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) The cervix constitutes the lower third of the uterus. It is in two parts, the endocervix and the ectocervix. Ectocervix is covered with squamous epithelium. Endocervix
Cytopathology. Robert M Genta Pathologie Clinique Université de Genève
Cytopathology Robert M Genta Pathologie Clinique Université de Genève Learning objectives At the end of this hour you will know: 1. What cytopathology is 2. How specimens are collected, processed, and
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future.
P16 et Ki67 Biomarkers: new tool for risk management and low grade intraepithelial lesions (LGSIL): be ready for the future. Mark H Stoler, MD University of Virginia Health System, Charlottesville, VA,
NEWER DEVELOPMENTS IN CYTOLOGY
NEWER DEVELOPMENTS IN CYTOLOGY ANURADHA K. MURTHY Metropolis Healthcare Ltd 2 nd September 2012 Introductory Comments & Historical perspectives CERVICAL NEOPLASIA George Papanicolaou Arrived in New York
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA
Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA Cancer Care Ontario Cervical Cancer Screening Goals Increase patient participation in cervical screening Increase primary care
CERVIX. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb.
CERVIX MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb. CERVIX Most cervical lesions are: Most are Cervicitis. cancers ( common in women worldwide). CERVICITIS Extremely
Biomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
The society for lower genital tract disorders since 1964.
The society for lower genital tract disorders since 1964. Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$
!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$ Updated Consensus Guidelines for Managing Abnormal Cervical Cancer Screening Tests and Cancer Precursors American Society for and Cervical Pathology
Taking Laboratory Coding for a Spin. Corrie Alvarez, CPC, CPMA, CPC-I, CEDC
Taking Laboratory Coding for a Spin Corrie Alvarez, CPC, CPMA, CPC-I, CEDC Agenda Overview of Laboratory Discuss Common Laboratory Terms Coding Guidelines Review Drug Testing, Anatomical Pathology Discuss
Becoming a colposcopist: Colposcope case studies
Becoming a colposcopist: Colposcope case studies Seon-Kyung Lee, M.D. Department of Obstetrics and Gynecology College of Medicine, Kyung Hee University Value of Colposcopy Cytology is an effective screening
Cervical Dysplasia and HPV
Cervical Dysplasia and HPV J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse HPV Double stranded DNA virus The HPV infect epithelial cells of the skin and mucous membranes Highest risk
Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure
The Korean Journal of Pathology 2012; 46: 359-364 ORIGINAL ARTICLE Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure Joon Seon Song Ilseon
HPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
TISSUE TUMOR MARKER EXPRESSION IN
TISSUE TUMOR MARKER EXPRESSION IN NORMAL CERVICAL TISSUE AND IN CERVICAL INTRAEPITHELIAL NEOPLASIA, FOR WOMEN WHO ARE AT HIGH RISK OF HPV (HUMAN PAPILLOMA VIRUS INFECTION). Raghad Samir MD PhD Verksamhet
Study of Cervical Pap Smears in a Tertiary Hospital
250 Original Study Study of Cervical Pap Smears in a Tertiary Hospital Sunita A. Bamanikar, Professor, Department of Pathology, Dadaso S. Baravkar, Resident Pathologist, Department of Pathology, Shirish
Comparative Study of Pap Smear and Cervical Biopsy Findings
Original paper Comparative Study of Pap Smear and Cervical Biopsy Findings ^* ^Department of pathology/ College of medicine/ Kerbala University/Kerbala/ Iraq. Abstract B ackground: Pap smear is the most
The LAST Guidelines in Clinical Practice. Implementing Recommendations for p16 Use
AJCP / Original Article The LAST Guidelines in Clinical Practice Implementing Recommendations for p16 Use Lani K. Clinton, MD, PhD, 1,2 Kyle Miyazaki, 1 Asia Ayabe, 1 James Davis, PhD, 2 Pamela Tauchi-Nishi,
Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens
Cervicovaginal Cytology: Normal and Abnormal Cells and Adequacy of Specimens 3 Christine Bergeron, MD, PhD Introduction Carcinoma of the cervix is a slow growing cancer, which is preceded by precancerous
The Bethesda System for Reporting Cervical Cytology: A Historical Perspective
Commentary Received: May 17, 2017 Accepted after revision: May 18, 2017 Published online: July 11, 2017 The Bethesda System for Reporting Cervical Cytology: A Historical Perspective Ritu Nayar a David
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
Prepared By Jocelyn Palao and Layla Faqih
Prepared By Jocelyn Palao and Layla Faqih The structure of the suspected atypical cell should always be compared to the structure of other similar, benign, cells which are present in the smears. The diagnosis
GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED
GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED This guideline is a revised version of the guideline developed in February 2000, by the Cervical Cancer Screening Working Group. This revised version
2016 myresearch Science Internship Program: Laboratory Medicine. Civic Education Office of Government and Community Relations
2016 myresearch Science Internship Program: Laboratory Medicine Civic Education Office of Government and Community Relations Aliya Ansari Science Internship Program: Laboratory Medicine Cytologic Differentiation
Kusepõis. Periuretraalne tsoon. Tsentraalne tsoon. Trasitsionaalne tsoon. Eesmine fibromuskulaarne. Perifeerne tsoon. tsoon. Ureetra.
Enn Jõeste PER Patoloogiakeskuse patoloog Head kolleegid! Uroloogide ja patoloogide seas on viimastel aastatel järjest enam päevakorrale tõusnud ühine soov parandada arusaamist kliiniliste ja morfoloogiliste
Department of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018
Document Title: Department of Health Standard for the Cervical Cancer Screening Program Document Ref. Number: DOH/CCSC/SD/1.0 Version: 1.0 Approval Date: 08 May 2018 Effective Date: 13 May 2018 Last Reviewed:
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
Cytomorphologic Features According to HPV DNA Type in Histologically Proven Cases of the Uterine Cervix
The Korean Journal of Pathology 2011; 45: 612-620 http://dx.doi.org/10.4132/koreanjpathol.2011.45.6.612 Cytomorphologic Features According to HPV DNA Type in Histologically Proven Cases of the Uterine
European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs
European Union survey on organization and quality control of cervical cancer screening and HPV vaccination programs Introduction to the Survey The purpose of this project is to collect information regarding
Histopathological Correlation with Cervical Cytology
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 11 Ver. VIII (November. 2016), PP 53-58 www.iosrjournals.org Histopathological Correlation
PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim
Department of Pathology, Kathmandu Medical College & Teaching Hospital, Sinamangal, Kathmandu, Nepal
Kathmandu University Medical Journal (2007), Vol. 5, No. 4, Issue 20, 461-467 Original Article Correlation of PAP smear findings with clinical findings and cervical biopsy Pradhan B 1, Pradhan SB 2, Mital
CINtec p16 INK4a Staining Atlas
CINtec p16 INK4a Staining Atlas Rating Rating Positive The rating positive will be assigned if the p16 INK4a -stained slide shows a continuous staining of cells of the basal and parabasal cell layers of
A Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,
Correlation Between Hybrid Capture II High-Risk Human Papillomavirus DNA Test Chemiluminescence Intensity From Cervical Samples With Follow-Up Histologic Results A Cytologic/Histologic Review of 367 Cases
Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure
Disclosure Workshop: Case Management of Abnormal Pap Smears and Colposcopies Rebecca Jackson, MD Associate Professor Obstetrics, Gynecology & Reproductive Sciences and Epidemiology & Biostatistics This
Comparative Study of Pap Smear Quality by using Ayre s Spatula versus Ayre s Spatula and Cytobrush Combination
ORIGINAL ARTICLE Comparative Study of Pap Smear Quality by using Ayre s Spatula versus Ayre s Spatula and Cytobrush Combination Numi Anjum 1, B Sindhoora 2 1. Tutor, Department of Obstetrics and Gynecology
A Study on Diagnostic Accuracy of Cervical Pap Smear by Correlating with Histopathology in a Tertiary Care Centre
Original Article DOI: 10.21276/APALM.1878 A Study on Diagnostic Accuracy of Cervical Pap Smear by Correlating with Histopathology in a Tertiary Care Centre Rachana L Y, S.S. Hiremath*, Prabhu M H, S.S
Human Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
Effect of human papillomavirus vaccination on cervical cancer screening in Alberta
Effect of human papillomavirus vaccination on cervical cancer screening in Alberta Presenter: Jong Kim 1 Team: Christopher Bell 2, Maggie Sun 3, Gordon Kliewer 3, Linan Xu 3, Maria McInerney 4, Lawrence
Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
CLINICAL RESEARCH. Background:
CLINICAL RESEARCH e-issn 1643-3750 DOI: 10.12659/MSM.895227 Received: 2015.07.04 Accepted: 2015.08.26 Published: 2015.12.10 Analysis of Sensitivity, Specificity, and Positive and Negative Predictive Values
Cervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
L impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du cancer du col uterin
10 es Journées annuelles de santé publique Palais des congrès de Montréal 23 au 27 octobre 2006 L impact attendu de la vaccination contre le virus du papillome humain sur les pratiques de dépistage du
Over-diagnoses in Cytopathology: Is histology the gold standard?
Over-diagnoses in Cytopathology: Is histology the gold standard? Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Faculty Disclosures: Teresa M. Darragh,
Uterine Cervical Smear Patterns In Females Attending A Teaching Hospital In Rural Eastern Uttar Pradesh, INDIA.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 9 Ver. II (September. 2016), PP 45-49 www.iosrjournals.org Uterine Cervical Smear Patterns
76 Arch Pathol Lab Med Vol 138, January 2014 p16 Utilization in Cervical Biopsies Singh et al
Variability of Pathologists Utilization of p16 and Ki-67 Immunostaining in the Diagnosis of Cervical Biopsies in Routine Pathology Practice and Its Impact on the Frequencies of Cervical Intraepithelial
ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION
Electronic Journal of Pharmacology and Therapy Vol 4, 15-20 (2011) ISSN: 0973-9890 (Available online at wwwtcrjournalscom) Clinical Article ndexed in: ProQuest database Abstract, USA (ProQuest Science
Protocol for an integrated data request of test results from the laboratories of pathological anatomy
Protocol for an integrated data request of test results from the laboratories of pathological anatomy Cancer diagnoses & early detection of cancer (breast, colorectal and cervix) CODAP page 1 Table of
Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
Transformation of Gynaecologic cytology: A Liquid Based Approach
Transformation of Gynaecologic cytology: A Liquid Based Approach Dr KIRTI CHADHA MD(PATH),PDCC(ONCOPATH) CONSULTANT SURGICAL PATHOLOGIST METROPOLIS HEALTHCARE LTD MUMBAI Carcinoma Cervix Used to be the
HPV Vaccine Protein L1 Predicts Disease Outcome of High-Risk HPV+ Early Squamous Dysplastic Lesions
Anatomic Pathology / Predictive Value of HPV Protein L1 HPV Vaccine Protein L1 Predicts Disease Outcome of High-Risk HPV+ Early Squamous Dysplastic Lesions Henrik Griesser, MD, 1 Heinz Sander, MD, 2 Cindy
National Cervical Screening Program MBS Item Descriptors
National Cervical Screening Program MBS Item Descriptors Item Item descriptor 73070 A test, including partial genotyping, for oncogenic human papillomavirus that may be associated with cervical pre-cancer
ACGME Competency / Milestone Assessment. The Pap Test. Ricardo R. Lastra, MD Zubair W. Baloch, MD, PhD
1 ACGME Competency / Milestone Assessment The Pap Test Ricardo R. Lastra, MD Zubair W. Baloch, MD, PhD Department of Pathology & Laboratory Medicine University of Pennsylvania, Perelman School of Medicine
I have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT
PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT QUESTION #1 WHICH OF THE FOLLOWING IS NOT A RISK FACTOR FOR CERVICAL CANCER? A. HIGH RISK HPV B. CIGARETTE SMOKING C.
Disclosures Teresa M Darragh, MD
Below the Belt: Screening for HPV-associated Cancers Teresa M. Darragh, MD UCSF Departments of Pathology and Obstetrics, Gynecology & Reproductive Sciences Disclosures Teresa M Darragh, MD Hologic: Research
I have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics